Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
Authors:
- Simone ParisiSimone Parisi
- Andrea BeccioliniABAndrea Becciolini
- Maria Chiara DittoMDMaria Chiara Ditto
- Davide RozzaDRDavide Rozza
- Anna ZanettiAZAnna Zanetti
- Angela LaganàALAngela Laganà
- Clara Lisa PeroniCPClara Lisa Peroni
- Chiara Centanaro Di VittorioCVChiara Centanaro Di Vittorio
- Rosanna DegiovanniRDRosanna Degiovanni
- Cristina RealmutoCRCristina Realmuto
- Carlo Alberto ScirèCSCarlo Alberto Scirè
- Marta PrioraMPMarta Priora
Open Access
- 26 January 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 621
Abstract
We evaluated the 3-year drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, previously treated with etanercept (ETA). Drug survival rate was calculated using the Kaplan–Meier method and Cox proportional hazard models were developed to examine predictors of SB4 discontinuation. 236 patients (120 RA, 80 PsA and 36 AS), aged 60.7 ± 13.8 years and with an ETA duration of 4.1 ± 3.4 years were included. The 3-year retention rate for SB4 was 94.4%, 88% and 86% in AS, RA and PsA patients, respectively, with no difference between groups. Patients without comorbid disease had higher retention rates vs. patients with comorbid disease (90% vs. 60%, p < 0.0001). Disease activity, as measured by DAS28, DAPSA and BASDAI remained stable over the 3 years. Comorbid disease (hazard ratio; HR: 4.06, p < 0.0001) and HAQ at baseline (HR: 2.42, p = 0.0024) significantly increased the risk of SB4 discontinuation, while previous ETA duration was negatively associated with SB4 discontinuation (HR: 0.97, p = 0.0064). Forty-one (17.4%) patients left the study due to the interruption of the SB4 treatment, 31 (75.6%) discontinued due to inefficacy and 10 (24.4%) due to adverse events. This real-life study confirms the similar efficacy profile of ETA with long-term retention and a good safety profile in inflammatory arthritis patients.Keywords
This publication has 36 references indexed in Scilit:
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapyAnnals of the Rheumatic Diseases, 2017
- Rheumatoid arthritisThe Lancet, 2016
- Global Prevalence of Spondyloarthritis: A Systematic Review and Meta‐Regression AnalysisArthritis Care & Research, 2016
- A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjectsBritish Journal of Clinical Pharmacology, 2016
- Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?RMD Open, 2015
- The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28).2014
- Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2014
- TNF inhibitor therapy for rheumatoid arthritisBiomedical Reports, 2012
- Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseasesArthritis Research & Therapy, 2009
- The Health Assessment Questionnaire (HAQ).2005